Danaher's exhibition booth at the fifth China International Import Expo [Photo/WeChat account: hongqiaoshangwuqu]
This year marks the 15th year since Danaher registered its operations in China and the fifth time the company has taken part in the China International Import Expo (CIIE).
Headquartered in the Shanghai Hongqiao International Central Business District (CBD), Danaher China has built 14 factories and nearly 20 research and development teams across the country.
The company's businesses in the Chinese market cover life science, bio-technology, medical diagnoses, water quality management and product identification.
In 2021, the United States-based science and technology company's operating revenue in China totaled $4 billion, an increase of more than 30 percent.
During this year's CIIE, Danaher showcased its significant advantages in the big health field and its innovation achievements through localization, aiming to seek more partners to jointly boost China's health industry.
Hongqiao CBD's orientation of industrial development corresponds to Danaher's development plan in China, according to a senior executive of the company.
Early this year, Danaher launched its 4.0 localization strategy in China and the policy support of Hongqiao CBD is expected to help the company become a new model of localization for multinationals.
In addition, the abundant medical resources in Hongqiao CBD, including the Hongqiao International Medical Center and a biomedicine headquarters park, are expected to provide strong support to the research, development and trade of international medicine and devices, which is a shot in the arm for Danaher's future expansion in China.
